Načítá se...

The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing

In the European Union and Canada, an Ann Arbor strain live attenuated influenza vaccine (LAIV) is approved for use in children aged 2–17 years, including those with mild to moderate asthma or prior wheezing. The safety and efficacy of LAIV versus trivalent inactivated influenza vaccine (TIV) in chil...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Ambrose, C. S., Dubovsky, F., Yi, T., Belshe, R. B., Ashkenazi, S.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer-Verlag 2012
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3456911/
https://ncbi.nlm.nih.gov/pubmed/22410646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10096-012-1595-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!